Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- PULM
- Price
- 2.42
- Stock movement down
- -0.01 (-0.62%)
- Company name
- Pulmatrix Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 8.84M
- Ent value
- 4.29M
- Price/Sales
- 2946.18
- Price/Book
- 1.87
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -36.13%
- 1 year return (CAGR)
- -67.69%
- 3 year return (CAGR)
- -13.20%
- 5 year return (CAGR)
- -42.88%
- 10 year return (CAGR)
- -42.08%
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
PULM does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 2946.18 |
| Price to Book | 1.87 |
| EV to Sales | 1431.18 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 3.65M |
| EPS (TTM) | -1.70 |
| FCF per share (TTM) | -1.64 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 3.00K |
| Gross profit (TTM) | -36.00K |
| Operating income (TTM) | -6.21M |
| Net income (TTM) | -6.22M |
| EPS (TTM) | -1.70 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -1200.00% |
| Operating margin (TTM) | -207100.00% |
| Profit margin (TTM) | -207333.33% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.79M |
| Net receivables | 0.00 |
| Total current assets | 4.97M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 4.98M |
| Accounts payable | 69.00K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 249.00K |
| Total liabilities | 249.00K |
| Shareholder's equity | 4.73M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -5.99M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -5.99M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -131.42% |
| Return on Assets | -124.85% |
| Return on Invested Capital | -131.42% |
| Cash Return on Invested Capital | -126.52% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.45 |
| Daily high | 2.50 |
| Daily low | 2.36 |
| Daily Volume | 16K |
| All-time high | 3575.00 |
| 1y analyst estimate | 10.00 |
| Beta | 1.71 |
| EPS (TTM) | -1.70 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| PULM | S&P500 | |
| Current price drop from All-time high | -99.93% | -1.82% |
| Highest price drop | -99.95% | -56.47% |
| Date of highest drop | 27 Mar 2024 | 9 Mar 2009 |
| Avg drop from high | -88.79% | -10.84% |
| Avg time to new high | 599 days | 12 days |
| Max time to new high | 2978 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
8.84M
Marketcap category
Small-cap
Description
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor compounds. The company was founded in 2003 and is headquartered in Framingham, Massachusetts.
Employees
2
Website
Investor relations
-
SEC filings
CEO
Teofilo Raad
Country
USA
City
Lexington
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page